Indoco Remedies Beheer

Beheer criteriumcontroles 3/4

De CEO Indoco Remedies is Sundeep Bambolkar, benoemd in Feb2012, heeft een ambtstermijn van 12.75 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 75.54M, bestaande uit 61.7% salaris en 38.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde ₹ 51.97M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.9 jaar en 14 jaar.

Belangrijke informatie

Sundeep Bambolkar

Algemeen directeur

₹75.5m

Totale compensatie

Percentage CEO-salaris	61.7%
Dienstverband CEO	12.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	7.9yrs
Gemiddelde ambtstermijn bestuur	14yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sundeep Bambolkar's beloning veranderd ten opzichte van Indoco Remedies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹321m
Jun 30 2024	n/a	n/a	₹767m
Mar 31 2024	₹76m	₹47m	₹985m
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹65m	₹40m	₹1b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹46m	₹30m	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹28m	₹20m	₹930m
Dec 31 2020	n/a	n/a	₹734m
Sep 30 2020	n/a	n/a	₹571m
Jun 30 2020	n/a	n/a	₹393m
Mar 31 2020	₹18m	₹15m	₹241m
Dec 31 2019	n/a	n/a	₹302m
Sep 30 2019	n/a	n/a	₹264m
Jun 30 2019	n/a	n/a	₹111m
Mar 31 2019	₹15m	₹12m	-₹29m
Mar 31 2018	₹16m	₹12m	₹412m

Compensatie versus markt: De totale vergoeding ($USD 895.38K ) Sundeep } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 267.06K ).

Compensatie versus inkomsten: De vergoeding van Sundeep is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sundeep Bambolkar (64 yo)

12.8yrs

Tenure

₹75,540,000

Compensatie

Mr. Sundeep Vasant Bambolkar has been a Joint Managing Director at Indoco Remedies Limited since February 15, 2012. Mr. Bambolkar served as Chief Financial Officer at Indoco Remedies Limited from March 23,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Suresh Kare	Non-Executive Chairman & Whole time Director	61.3yrs	₹36.89m	4.7% ₹ 1.3b
Sundeep Bambolkar	Joint MD & Executive Director	12.8yrs	₹75.54m	0.18% ₹ 52.0m
Aditi Panandikar	MD & Executive Director	12.8yrs	₹85.42m	6.11% ₹ 1.7b
Pramod Ghorpade	Chief Financial Officer	3yrs	₹17.38m	geen gegevens
Ramanathan Hariharan	GM of Legal	1.9yrs	₹5.48m	geen gegevens
Kavita Inamdar	Chief Technical Officer	no data	₹7.57m	geen gegevens
Ajay Karajagi	President of Sales & Marketing	no data	geen gegevens	geen gegevens
Rajesh Usgaonker	Chief Marketing Officer	no data	geen gegevens	geen gegevens
Rajan Saawant	Vice President of Corporate HR	no data	geen gegevens	geen gegevens
Prashant Pathak	Head of OSD	no data	geen gegevens	geen gegevens
Abhilash Soral	Executive Vice President of International Business for Regulated Markets	no data	geen gegevens	geen gegevens
Hemant Joshi	Senior Vice President of Sales for API	no data	geen gegevens	geen gegevens

7.9yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 532612 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Suresh Kare	Non-Executive Chairman & Whole time Director	61.3yrs	₹36.89m	4.7% ₹ 1.3b
Sundeep Bambolkar	Joint MD & Executive Director	20.7yrs	₹75.54m	0.18% ₹ 52.0m
Aditi Panandikar	MD & Executive Director	20.7yrs	₹85.42m	6.11% ₹ 1.7b
Divakar Gavaskar	Independent Non-Executive Director	19.6yrs	₹580.00k	geen gegevens
Rajiv Kakodkar	Independent Non-Executive Director	17.6yrs	₹660.00k	0.013% ₹ 3.7m
Anand Nadkarni	Non-Executive Director	10.5yrs	₹360.00k	geen gegevens
Vasudha Kamat	Non-Executive & Independent Director	4.7yrs	₹500.00k	geen gegevens
Abhijit Gore	Independent Non-Executive Director	4.1yrs	₹460.00k	0.0054% ₹ 1.5m
Satish Shenoy	Independent Director	less than a year	geen gegevens	geen gegevens
Ajay Mulgaokar	Independent Director	less than a year	geen gegevens	geen gegevens

14.0yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 532612 zijn ervaren en ervaren (gemiddelde ambtstermijn van 14 jaar).

Indoco Remedies Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Insufficient new directors

Recent updates

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Price target decreased by 8.8% to ₹360

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)

Consensus EPS estimates increase to ₹17.85

Investor sentiment improved over the past week

Chief Financial Officer Mandar Borkar has left the company

Full year 2021 earnings released: EPS ₹10.10 (vs ₹2.62 in FY 2020)

Indoco Remedies Limited Recommends Dividend for the Financial Year 2020-2021

Price target increased to ₹361

Indoco Announces the Launch of Brinzolamide Ophthalmic Suspension 1% in the US Market by Teva Pharmaceuticals

Third quarter 2021 earnings released: EPS ₹2.75 (vs ₹0.99 in 3Q 2020)

New 90-day high: ₹326

Indoco Remedies Limited to Report Q3, 2021 Results on Feb 09, 2021

New 90-day high: ₹313

Market bids up stock over the past week

New 90-day high: ₹290